NCT01990677

Eplerenone for the Treatment of Central Serous Chorioretinopathy

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 108 (actual)
• Sponsor: Wills Eye · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .

Detailed description

To evaluate the effect of oral eplerenone compared to placebo in patients with central serous chorioretinopathy (CSCR) on sub-foveal (small part of retina) fluid using optical coherence tomography (OCT).

Conditions

• Central Serous Chorioretinopathy

Interventions

Type	Name	Description
DRUG	25mg Eplerenone	Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo
DRUG	Placebo	Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.

Timeline

• Start date: 2013-10-01
• Primary completion: 2015-03-01
• Completion: 2015-05-01
• First posted: 2013-11-21
• Last updated: 2018-11-07
• Results posted: 2017-06-29

Locations

10 sites across 1 country: United States